ストックスクリーナーアプリを入手
1.645
3.46%
0.055
前日終値:
$1.59
開ける：
$1.57
24時間の取引高:
65,931
Relative Volume:
0.24
時価総額：
$43.03M
収益：
$1.79M
当期純損益:
$-70.90M
株価収益率:
-0.1059
EPS:
-15.54
ネットキャッシュフロー:
$-34.95M
1週間 パフォーマンス:
+8.22%
1か月 パフォーマンス:
-17.34%
6か月 パフォーマンス:
-58.46%
1年 パフォーマンス:
-38.64%
1日の値動き範囲:
$1.57
$1.66
1週間の範囲:
$1.46
$1.66
52週間の値動き範囲:
$1.46
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
名前
Senti Biosciences Inc
セクター
電話
(650) 239-2030
住所
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.645 | 41.86M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-06 | 開始されました | Laidlaw | Buy |
| 2022-10-07 | 開始されました | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc (SNTI) 最新ニュース
Key resistance and support levels for Senti Biosciences Inc.Portfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What technical models suggest about Senti Biosciences Inc.’s comeback2025 Year in Review & Daily Stock Trend Reports - Newser
Top chart patterns to watch in Senti Biosciences Inc.2025 Key Highlights & Smart Swing Trading Alerts - Newser
Will Senti Biosciences Inc. benefit from macro trendsTrade Analysis Summary & Safe Swing Trade Setups - Newser
Using economic indicators to assess Senti Biosciences Inc. potentialPortfolio Return Report & Stock Portfolio Risk Management - Newser
How to integrate Senti Biosciences Inc. into portfolio analysis toolsMarket Growth Review & High Conviction Investment Ideas - Newser
Does Senti Biosciences Inc. have declining or rising EPSWeekly Loss Report & Community Shared Stock Ideas - thegnnews.com
Will Senti Biosciences Inc. announce a stock split2025 Geopolitical Influence & Stepwise Entry and Exit Trade Signals - newsyoung.net
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - 富途牛牛
Senti Biosciences to present at Webull Financial Corporate Connect webinar. - AInvest
Senti Bio CEO to Showcase Gene Circuit Platform at Webull's Biotech Investment Series - Stock Titan
Senti Biosciences Posts Increased Losses Amid Strategic Moves and Raising $35.2M in Private Placement - AInvest
Senti Biosciences Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 WrapUp & Verified High Yield Trade Plans - beatles.ru
Laidlaw Initiates Coverage on Senti Bio with Buy Rating and $5 Target Price - AInvest
Is This a Bottoming Phase for Senti Biosciences Inc.2025 Valuation Update & Risk Managed Investment Signals - beatles.ru
Senti Biosciences Reports Increased Losses Amid Strategic Moves - TipRanks
Senti Biosciences shares rise 3.38% after-hours after announcing Phase 2 dose selection for SENTI-202. - AInvest
Senti Biosciences shares fall 1.32% intraday after announcing participation in a Virtual Investor 'What This Means' segment. - AInvest
Senti Bio Participates in Virtual Investor 'What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment Advances: Senti Bio Reveals Phase 2 Dosing Strategy for Novel CAR-NK Cell Therapy - Stock Titan
Momentum divergence signals in Senti Biosciences Inc. chartTrading Opportunities Forecast by AI Insight - Newser
What makes Senti Biosciences Inc. stock price move sharplyReal Market Tracker with Price Action Tools - Newser
Senti Biosciences Inc. stock chart pattern explainedLow Exposure Strategy with Sector Analysis - Newser
Senti Biosciences Inc. Stock Fails to Break Resistance Traders ReactIntraday Trend Analysis for Fast Gains Released - beatles.ru
Using data tools to time your Senti Biosciences Inc. exitBreakout Monitoring with Momentum Analysis - Newser
Chardan Capital Reaffirms “Buy” Rating for Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences Inc Reports Q2 2025 Earnings: EPS at -$0.56, Revenue Misses Estimates at $0 Million - AInvest
Senti Biosciences: Chardan Capital Raises Buy Rating, PT to $12 - AInvest
Senti Biosciences: A High-Risk Bet on Biotech's Future? - AInvest
Senti Biosciences completes dose finding in AML therapy trial By Investing.com - Investing.com Australia
Senti Biosciences completes dose finding in AML therapy trial - Investing.com
Senti Bio reports Q2 results, SENTI-202 clinical development advances. - AInvest
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - The Manila Times
Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan
How Senti Biosciences Inc. stock performs during market volatilityTen-Year Sector Performance and Summary Analysis - Newser
Sandstorm Gold Royalties Backs Royal Gold’s Kansanshi Acquisition - The Globe and Mail
Senti Biosciences shares rise 3.49% premarket after confirming recommended Phase 2 dose for SENTI-202. - AInvest
Tools to assess Senti Biosciences Inc.’s risk profileAnnual Market Behavior and Sector Summary - Newser
Will Senti Biosciences Inc. stock recover after recent dropIn-Depth Stock Trading Volume Analysis - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialConsistent Gain Plan with AI Support - Newser
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - The Manila Times
Breakthrough AML Treatment: Senti Bio's Cell Therapy Shows 67% Complete Remission at Phase 2 Dose - Stock Titan
Senti Biosciences Inc. Forms Double Bottom Pattern — Eyes on BreakoutConsistent Gain Investment Strategies Emerge - metal.it
Is Senti Biosciences Inc. stock entering bullish territoryFree Sector Based Breakout Stock Forecast - Newser
What is Senti Biosciences Inc. company’s growth strategyAchieve consistent profits with proven methods - Jammu Links News
How does Senti Biosciences Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What are the technical indicators suggesting about Senti Biosciences Inc.Capitalize on market momentum for maximum gains - Jammu Links News
Is Senti Biosciences Inc. stock overvalued or undervaluedFree Stock Market Real-Time Monitoring - Jammu Links News
Why Senti Biosciences Inc. stock attracts strong analyst attentionFast Entry Strategy with Price Prediction - Newser
Senti Biosciences Inc (SNTI) 財務データ
収益
当期純利益
現金流量
EPS
Senti Biosciences Inc (SNTI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):